| Name | Title | Contact Details |
|---|
Evidation Health is a technology and services company that helps individuals and the world`s most innovative healthcare companies understand and influence the everyday behaviors that create better health outcomes. Evidation pairs a first of its kind discovery engine designed for better, faster, and more efficient studies with a delivery platform that connects individuals and the healthcare industry, including life sciences organizations, providers, payers, and digital health companies. The company`s technology is designed to be entirely privacy-safe and individually-permissioned. Evidation Health`s mission is to enable and empower everyone to participate in better health outcomes. The company is headquartered in San Mateo, CA, with additional offices in Santa Barbara, CA.
Gauthier Biomedical is a Grafton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedeAnalytics provides evidence-based insights to solve a real problem that plagues health care – how to use the immense amount of patient data collected along the care continuum to deliver cost – effective care and promote a healthier population. The platform delivers intelligence that helps healthcare organizations detect their greatest areas of risk and identify opportunities to improve their financial health. It empowers providers and health plans to collaborate and use data to strengthen their operations and improve the quality of care. MedeAnalytics` cloud-based tools have been used to analyze more than 21 billion patient encounters in the United States and United Kingdom, providing better care to more than 30 million patients and better business for 900 healthcare organizations.
Stratis Health is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.